GRAND RAPIDS, Mich. , Aug. 12, 2024 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company announced today its participation in the successful Series A extension round of Prana Thoracic, a Houston -based medtech startup.
The round, which was oversubscribed by 30%, secured an additional $3 million , bringing Prana Thoracic's total funding to $9 million . This achievement underscores the strong confidence in Prana Thoracic's mission to revolutionize lung cancer intervention through precision surgical solutions. "We are excited to support Prana Thoracic in their mission to improve lung cancer treatment.
Their innovative approach has the potential to significantly impact patient outcomes," said R. Sean Churchill,MD, MBA - Managing Director of cultivate(MD). Prana Thoracic's cutting-edge approach to lung cancer treatment aligns with cultivate(MD)'s commitment to investing in transformative healthcare technologies.
The company's pioneering work in developing minimally invasive techniques for lung tissue excision has the potential to dramatically improve patient outcomes, offering earlier and more precise interventions for those affected by lung cancer. "We are grateful for the overwhelming support from our investors in this financing round. Their confidence in our mission and plan is motivating," said Joanna Nathan , Chief Executive Officer and Co-Founder of Prana Thoracic.
"This additional funding will enable us to accelerate our efforts in bringing precis.